Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation ...

Minimal residual disease (MRD) is being used more frequently in clinical trials and to identify the best treatment course for patients, but unknowns remain about the optimal use of MRD testing. While ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is negative. Enrollment in clinical trials is recommended for MRD-positive ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy. After undergoing treatment — including a stem ...

>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey 85% of surveyed patients have heard of MRD testing, yet ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

A two-time breast cancer survivor who was diagnosed with chronic lymphocytic leukemia in 2020 discussed her belief in the power of minimal residual disease testing. Two-time breast cancer survivor Sue ...

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic ...